← 返回

抗 PD-1 通过增强黑色素瘤浸润性 T(h)1 样 Foxp3(+) 调节性 T 细胞中的共刺激作用来减轻局部免疫抑制

英文原题:Anti-PD-1 amplifies costimulation in melanoma-infiltrating T(h)1-like Foxp3(+) regulatory T cells to alleviate local immunosuppression.

查看英文原题

Anti-PD-1 amplifies costimulation in melanoma-infiltrating T(h)1-like Foxp3(+) regulatory T cells to alleviate local immunosuppression.

PubMed 2025/01/06(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

PD-1 阻断促进共表达 PD-1 和 Helios 的高度活化 T reg 细胞亚群的扩增。虽然这些细胞在肿瘤环境外具有强效抑制作用,但肿瘤微环境中存在的共刺激和炎症信号导致其局部获得 T h 1 样特征并丧失对效应 T 细胞的抑制作用。

研究思路结论见上方概要

靶向程序性细胞死亡蛋白-1(PD-1)的免疫检查点抑制剂是包括黑色素瘤在内的许多实体瘤的一线治疗方法。PD-1阻断增强了黑色素瘤浸润性CD8+ T细胞的效应功能,导致持久的肿瘤缓解。然而,55%的黑色素瘤患者对治疗无反应。由于Foxp3+调节性T(T reg)细胞在肿瘤诱导的免疫抑制中发挥重要作用并表达PD-1,我们假设抗PD-1也会增强黑色素瘤浸润性T reg细胞的功能,这可能对治疗效果不利。

在携带高免疫原性且对PD-1阻断敏感的Yale University Mouse Melanoma Exposed to Radiation 1.7(YUMMER1.7)肿瘤的C57Bl/6 Foxp3报告小鼠中,评估了T reg细胞的细胞和功能动态。在肿瘤生长或治疗全程中检查了肿瘤和淋巴组织区室中的T reg细胞反应,并通过多参数流式细胞术分析进行离体评估,同时使用通过荧光激活细胞分选(FACS)分离的TIL(肿瘤浸润淋巴细胞)进行体外抑制试验,并通过空间蛋白质组学和转录组学分析进行原位评估。

在这个高度免疫原性的黑色素瘤模型中,抗PD-1单药治疗产生了高应答者(HRs)和低应答者(LRs)。我们表明,HR肿瘤特征性的强效CD8+ T细胞应答 paradoxically 与高度活化、表达Helios的T reg细胞的扩增同时发生。在HRs和LRs中,T reg细胞与CD8+ T细胞共定位于肿瘤的免疫原性区域,并在体外显示出强效的抑制能力。进一步表征显示,黑色素瘤浸润性T reg细胞逐步获得T-bet和干扰素γ表达,且仅见于HRs,而在体外诱导这种T辅助细胞1(Th1)样表型导致CD8+ T细胞逃避T reg细胞介导的抑制。利用空间蛋白质组学和转录组学分析,我们证明,在CD8:T reg细胞比值升高的HR肿瘤区域,T reg细胞显示出PI3K/Akt信号活性增加。

展开英文摘要原文

Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8 + T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment. As Foxp3 + regulatory T (T reg ) cells play an important role in tumor-induced immunosuppression and express PD-1, we hypothesized that anti-PD-1 also increases the functions of melanoma-infiltrating T reg cells, which could be detrimental to treatment efficacy.

The cellular and functional dynamics of T reg cells were evaluated in C57Bl/6 Foxp3-reporter mice bearing highly immunogenic and PD-1 blockade-sensitive Yale University Mouse Melanoma Exposed to Radiation 1.7 (YUMMER1.7) tumors. T reg cell responses in tumors and lymphoid compartments were examined throughout tumor growth or therapy and were assessed ex vivo by multiparametric flow cytometry analysis, with in vitro suppression assays using tumor-infiltrating lymphocytes isolated by fluorescence-activated cell sorting (FACS) and in situ through spatial proteomic and transcriptomic profiling.

In this highly immunogenic melanoma model, anti-PD-1 monotherapy yielded high responders (HRs) and low responders (LRs). We show that the potent CD8 + T cell responses characteristic of HR tumors paradoxically coincide with the expansion of highly-activated, Helios-expressing T reg cells. In both HRs and LRs, T reg cells co-localize with CD8 + T cells in immunogenic regions of the tumor and display potent suppressive capacity in vitro. Further characterization revealed that melanoma-infiltrating T reg cells progressively acquire T-bet and interferon gamma expression, exclusively in HRs, and induction of this T helper cell 1 (T h 1)-like phenotype in vitro led to CD8 + T cell evasion from T reg cell-mediated suppression. Using spatial proteomic and transcriptomic profiling, we demonstrate that T reg cells display an increased activity of PI3K/Akt signaling in regions of HR tumors with an elevated CD8:T reg cell ratio.

PD-1 blockade promotes the expansion of a subset of highly-activated T reg cells coexpressing PD-1 and Helios. While these cells are potently suppressive outside tumor environments, costimulatory and inflammatory signals present in the tumor microenvironment lead to their local acquisition of T h 1-like characteristics and loss of suppression of effector T cells.

论文信息

作者
Attias M、Alvarez F、Al-Aubodah TA、Istomine R、McCallum P、Huang F、Sleiman A、Nishimura T
第一作者单位
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.Canada
通讯作者单位
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada ciro.piccirillo@mcgill.ca.Canada
期刊
Journal for immunotherapy of cancer2025 Jan 6
原文标识
PubMed 39762077 · DOI 10.1136/jitc-2024-009435